Compare Bristol-Myers Squibb Co (BMY) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.8 (market cap $116.30B), while Global X NASDAQ 100 Covered Call ETF trades at $18.26. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals.
| BMY | QYLD | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $18.52 |
52-Week Low | $42.60 | $16.46 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
QYLD trades at $18.15, down 1.68% on the day, with technical indicators showing a neutral overall signal. The ETF's covered call strategy generates high monthly distributions but has historically lagged the Nasdaq-100's total return, with recent news highlighting NAV erosion despite consistent dividend payouts. Moving averages suggest a bullish trend while oscillators remain neutral, with all key support and resistance levels clustered around $18.
The outlook remains cautious as QYLD's high yield comes at the cost of capital appreciation potential. While attractive for income-focused investors, the strategy underperforms in strong bull markets. Key risks include capped upside and competitive pressure from lower-fee alternatives like GPIQ, requiring investors to prioritize income generation over growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
